Glenview Trust Co continued to hold its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,527 shares of the medical equipment provider’s stock at the end of the first quarter. Glenview Trust Co’s holdings in Zimmer Biomet Holdings were worth $553,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Prudential Financial Inc. boosted its stake in shares of Zimmer Biomet Holdings by 3.1% in the first quarter. Prudential Financial Inc. now owns 283,003 shares of the medical equipment provider’s stock worth $34,557,000 after buying an additional 8,555 shares in the last quarter. Quantbot Technologies LP boosted its stake in shares of Zimmer Biomet Holdings by 6.2% in the first quarter. Quantbot Technologies LP now owns 1,650 shares of the medical equipment provider’s stock worth $201,000 after buying an additional 96 shares in the last quarter. Aberdeen Asset Management PLC UK boosted its stake in shares of Zimmer Biomet Holdings by 12.3% in the first quarter. Aberdeen Asset Management PLC UK now owns 44,510 shares of the medical equipment provider’s stock worth $5,435,000 after buying an additional 4,889 shares in the last quarter. Delta Lloyd NV acquired a new stake in shares of Zimmer Biomet Holdings during the first quarter worth $12,278,000. Finally, Nordea Investment Management AB boosted its stake in shares of Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock worth $602,159,000 after buying an additional 987,398 shares in the last quarter. Institutional investors and hedge funds own 84.63% of the company’s stock.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 125.92 on Friday. The stock has a market cap of $25.39 billion, a P/E ratio of 51.54 and a beta of 1.23. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.21. The stock has a 50 day moving average of $120.97 and a 200-day moving average of $116.09.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.02. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. The business had revenue of $1.98 billion for the quarter, compared to analysts’ expectations of $1.96 billion. During the same period in the previous year, the business earned $2.00 earnings per share. The company’s revenue was up 3.8% on a year-over-year basis. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.54 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 23rd will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date is Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 39.67%.

COPYRIGHT VIOLATION NOTICE: “Zimmer Biomet Holdings, Inc. (ZBH) Position Held by Glenview Trust Co” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-position-held-by-glenview-trust-co/1372131.html.

A number of analysts recently weighed in on the stock. Citigroup Inc. increased their price target on shares of Zimmer Biomet Holdings from $108.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, June 9th. ValuEngine cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They set a “sell” rating and a $92.00 price target for the company. Canaccord Genuity reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a research note on Friday, April 28th. Finally, Oppenheimer Holdings, Inc. set a $132.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Friday, April 28th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has a consensus rating of “Buy” and an average price target of $135.88.

In related news, insider David C. Dvorak sold 1,040 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $121.63, for a total transaction of $126,495.20. Following the sale, the insider now directly owns 294,077 shares in the company, valued at $35,768,585.51. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David C. Dvorak sold 87,331 shares of Zimmer Biomet Holdings stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $116.47, for a total transaction of $10,171,441.57. Following the sale, the insider now owns 381,886 shares in the company, valued at $44,478,262.42. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 112,302 shares of company stock worth $13,230,422. Company insiders own 1.07% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.